Medicine Matters oncology

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in oncology

Learn more

New additions to the Adis Journal Club

Browse October's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

Five-year IMvigor210 data confirm first-line atezolizumab mUC benefit

EV-301 update: Enfortumab vedotin benefit maintained in hard-to-treat subgroups

Trastuzumab duocarmazine could be ‘a new option’ for HER2-positive metastatic breast cancer

Long-term effects of COVID-19 not uncommon in cancer patients

Combining LuPSMA with pembrolizumab ‘promising’ for mCRPC

MONALEESA-2 update demonstrates ribociclib plus letrozole OS benefit

IN FOCUS | ESMO Congress 2021

28-09-2021 | ESMO 2021 | Conference coverage | Video

ctDNA analysis may help to personalize metastatic urothelial carcinoma treatments

Guru Sonpavde outlines the findings of their immunotherapy study supporting a potential role for longitudinal ctDNA profiling to identify suitable therapies for people with metastatic urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

No new safety signals for neoadjuvant, maintenance atezolizumab in mesothelioma

Flexibility positively impacts lung cancer clinical trial participation in COVID-19 era

Pretreatment ctDNA levels may predict survival in neoadjuvant-treated NSCLC patients

Atezolizumab plus chemotherapy feasible for NSCLC with brain metastases

No OS benefit of lurbinectedin plus doxorubicin in relapsed SCLC

Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

Cancer surgery systems need strengthening against future societal lockdowns

Thoracic ultrasonography may lead to shorter pleurodesis hospital stays

TP53, KEAP1 mutations could be biomarkers for NSCLC survival

Pralsetinib receives nod from EMA for use in RET-positive NSCLC

FDA approves mobocertinib for advanced NSCLC with EGFR exon 20 insertions

No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

IN FOCUS | Lung & thoracic cancers

06-10-2021 | COVID-19 | News

CT analysis helps define COVID-19 vaccine-related axillary lymphadenopathy

An analysis of computed tomography scans from people with thoracic malignancies shows that approximately one in 11 people develop axillary lymphadenopathy following mRNA-based COVID-19 vaccination.

IN FOCUS | Genitourinary cancers

08-09-2021 | Prostate cancer | News

PRONOUCE fails to resolve CV safety questions for GnRH antagonists, agonists

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

High rates of tamoxifen discontinuation, nonadherence in male breast cancer patients

Adjuvant abemaciclib gets go-ahead from FDA for early breast cancer

Cancer surgery systems need strengthening against future societal lockdowns

Early data point to benefit of third COVID-19 vaccine dose for cancer patients

Thoracic ultrasonography may lead to shorter pleurodesis hospital stays

Toxicity Index, PRO data shed light on early endocrine therapy discontinuations

IN FOCUS | Breast cancer

07-10-2021 | Breast cancer | News

SLE is a risk factor for death in older women with breast cancer

Systemic lupus erythematosus is significantly associated with impaired survival among older women with early breast cancer, research findings show.

IN FOCUS | COVID-19 & cancer

06-10-2021 | COVID-19 | News

CT analysis helps define COVID-19 vaccine-related axillary lymphadenopathy

An analysis of computed tomography scans from people with thoracic malignancies shows that approximately one in 11 people develop axillary lymphadenopathy following mRNA-based COVID-19 vaccination.